Search for: "MONSANTO COMPANY V SYNGENTA SEEDS" Results 1 - 11 of 11
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
9 Nov 2010, 9:47 am by Guest Barista
In the event that some disaster befalls the company providing seeds, the farmer would be left high-and-dry. [read post]
8 May 2007, 3:43 am
Patent No. 5,924,302, entitled "Insulated shipping container"); discussion of the claim term "slidingly engage"; no literal infringement shown, and in this particular case, infringement under the doctrine of equivalents cannot be invoked (fact-specific case)Syngenta Seeds v. [read post]
23 Dec 2009, 12:40 am
: Proposed amendments to Plant Variety Statute (IP Osgoode) EU: German Federal Supreme Court referral to ECJ concerning embryonic stem cells and the Biotech Directive (EPLAW) EU: Data exclusivity and food claims in Europe - Commission authorises health claim on the effect of water-soluble tomato concentrate on platelet aggregation and grants protection of proprietary data under Regulation (EC) No 1924/2006 (IPKat) France: Pharma trade marks under threat - Senate and National Assembly approve law… [read post]
24 Aug 2007, 8:03 am
Syngenta Seeds, Inc., 443 F. [read post]
29 Mar 2021, 7:10 pm by admin
Although no rule or statute prohibits side switching, state and federal courts have exercised what they have called an inherent power to supervise and control ethical breaches by lawyers and expert witnesses.[1] The Wang Test Although certainly not the first case on side-switching, the decision of a federal trial court, in Wang Laboratories, Inc. v Toshiba Corp., has become a key precedent on disqualification of expert witnesses.[2] The test spelled out in the Wang case has generally been… [read post]
29 Jan 2024, 4:35 pm
https://responsibletechnology.org/ge-soil-microbes-new-target-for-agrichemical- companies/ Rhinos cont'd. [read post]
16 Aug 2008, 2:43 am
– discussion of Washington Post article on Ismed’s efforts to promote follow-on biologics approval pathway: (Patent Baristas), (Patent Docs), US: Congressional fact-finding on follow-on biologics: (Patent Docs), US: David v Monsanto: Biotechnology patent ‘exhaustion’ after Quanta, Supreme Court petition: (Hal Wegner), US: Ulysses Pharmaceuticals announces issuance of patent for novel class of ant [read post]